Rozanolixizumab

View Clinical trials for Rozanolixizumab Get Rozanolixizumab Patent Info for Free

Inn NameRozanolixizumab
Lab CodesUCB-7665
Chemical NameImmunoglobulin G4-kappa, anti-[Homo sapiens FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], humanized and chimeric monoclonal antibody; gamma4 heavy chain (1-444) humanized [humanized VH (Homo sapiens IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117)), Homo sapiens IGHG4*01 (CH1 (118- 215), hinge S10>P (225) (216-227),CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfide with kappa light chain chimeric (1’-219’) [synthetic V-KAPPA (Homo sapiens IGKV1-9*01 (76.00%) -Homo sapiens IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01, Km3 (113'-219')]; dimer (223-223":226-226")- bisdisulfide
Alternate NameImmunoglobulin G4, anti-(human fcrn receptor) (human-rattus norvegicus monoclonal UCB 7665 heavy chain), disulfide with human-rattus norvegicus monoclonal UCB 7665 light chain, dimer
SequenceHeavy chain
EVPLVESGGG LVQPGGSLRL SCAVSGFTFS NYGMVWVRQA PGKGLEWVAY 50
IDSDGDNTYY RDSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCTTGI 100
VRPFLYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444

Light chain
DIQMTQSPSS LSASVGDRVT ITCKSSQSLV GASGKTYLYW LFQKPGKAPK 50
RLIYLVSTLD SGIPSRFSGS GSGTEFTLTI SSLQPEDFAT YYCLQGTHFP 100
HTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 219

Disulfide bridges location
Intra-H (C23-C104) 22-96 144-200 258-318 364-422
22''-96'' 144''-200'' 258''-318'' 364''-422''
Intra-L (C23-C104) 23'-93' 139'-199'
23'''-93''' 139'''-199'''
Inter-H-L (CH1 10-CL 126) 131-219' 131''-219'''
Inter-H-H (h 8, h 11) 223-223'' 226-226''

N-glycosylation sites
H CH2 N84.4:
294, 294''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureRozanolixizumab.png
Cas Registry Number1584645-37-3
New Molecular EntityYes
OriginatorUCB
Mechanism Of ActionImmunomodulator
Who Atc CodesB06A (Other Hematological Agents)
L (Antineoplastic and Immunomodulating Agents)
Ephmra CodesB6 (All Other Haematological Agents)
L (Antineoplastic and Immunomodulating Agents)
IndicationImmunological diseases, Thrombocytopenia

Free counters!